MSHO's Navigator Conference

MSHO's Navigator Conference

Calling all nurses, nurse navigators, social workers or financial counselors. This conference is for you! This is a great opportunity to further your education in the field of oncology and to network with your peers. To learn more or to register, click the link below.
more information

MSHO's Annual Review in Oncology

MSHO's Annual Review in Oncology

MSHO and the University of Michigan will be co-hosting a one-day program in 2025, bringing together faculty from Michigan's cancer centers to share the latest information with practicing oncologists and hematologists, aiming to enhance the standard of care and knowledge base. To learn more or to register, click the link below.
more information

MSHO's Certified Medical Office Manager Hematology & Oncology Certification Course

MSHO's Certified Medical Office Manager Hematology & Oncology Certification (CMOM) Course

Calling all administrators who wish to become CMOM certified! MSHO is conducting the Certified Medical Office Manager (CMOM) Certification Course in partnership with the Practice Management Institute (PMI). Join us to grow your leadership and problem-solving skills. To learn more or to register, click the link below.
more information

May is Brain Cancer Awareness Month

May is Brain Cancer Awareness Month

In 2025, physicians will diagnose cancers of the brain or central nervous system in about 24,820 people in the United States, according to the National Cancer Institute (NCI), with around 18,330 of those dying from these cancers.

more information

NCCN Guidelines Updates

NCCN Guidelines Updates

May 13, 2025

NCCN Guidelines Updated for Smoking Cessation.

more information

Previous Next

Advocacy

MSHO continuously contacts legislators, provides comments to policy makers, and collaborates with payers on issues of concern to those delivering care to cancer patients.

more information

Education

It is important that our members are aware of meetings, webinars, and other educational opportunities specifically designed to address the complexities of cancer care.

more information

Research

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

more information

MSHO Foundation

The MSHO Foundation is a 501c3 organization which was formed in 2011 to address the growing educational needs of hematology and oncology professionals in Michigan.

more information

Job Board

MSHO offers our members an opportunity to share current job openings or post your resume as a job seeker on our website. Click here to view job openings, posted resumes, or to create a new post.

more information

MSHO's 40th Anniversary KudoboardJoin Us in Celebrating 40 Years of MSHO!

As we mark this milestone anniversary, we invite you to share your memories, messages, and photos on our MSHO 40th Anniversary Kudo Board! Whether it’s a story from past meetings, a special connection you made, or a moment that stands out - your contributions will help honor our journey and shape what’s next.

Add your message today and celebrate with us! https://www.kudoboard.com/boards/36YBWnwd. 

Upcoming Events view all events

 May 2025 
SMTWTFS
    123
456
789
10
11121314151617
18192021
22
2324
252627282930
31
Mon
9
2025
June 9, 2025

Navigator Conference

Crowne Plaza West, Lansing

view event details
Sat
28
2025
June 28, 2025

Annual Review in Oncology

Saint John's Resort, Plymouth

view event details
Fri
1
2025
August 1 - 16, 2025

Certified Medical Office Manager Hematology & Oncology Certification Course

AUGUST 1, 2, 15, 16

MSHO Office

view event details

Latest News view all news

FDA Approves AbbVie's EMRELIS™ (telisotuzumab vedotin-tllv) for Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
05/15/2025

FDA Approves AbbVie's EMRELIS™ (telisotuzumab vedotin-tllv) for Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
05/15/2025

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)

MSHO Featured in Detroit News on Medical Research Funding Cuts
04/03/2025

MSHO Featured in Detroit News on Medical Research Funding Cuts

Corporate Sponsors view all sponsors